Page 3 - Pharma Industry

Amid Covid, Pharma, healthcare industry looks to sustain momentum next year

Having proved its prowess to the world during the challenging times of the pandemic by supplying 60 per cent of the global COVID-19 vaccine requirements, the Indian pharma and healthcare industry is looking to build on the experience of the last two years, strengthen the partnership with the government and sustain the momentum in 2022. Organisation of Pharmaceutical Producers of India (OPPI) Director-General K G Ananthakrishnan told PTI that it is crucial for the industry to further build momentum towards the gains secured over the course of the pandemic which will help it carve a niche in the global pharma value chain. To this end, the industry must collectively work towards supporting, recognising, and rewarding high-risk research and development, he added. "Encouraging private sector investment in R&D and rewarding innovations through a strong intellectual property ecosystem along with the on-ground execution of the government's vision of Discover in India will spur the growth

Indian Covid vaccine makers bank on boosters as demand crashes

The SII, the world's biggest vaccine maker, and Sputnik's India distributor, Dr. Reddy's Labs, have both said they have approached health authorities about boosters

ACG to invest Rs 600 cr to build Asia's largest capsule plant in Maha

Global pharma industry supplier ACG on Tuesday said it will invest Rs 600 crore to build Asia's largest capsules manufacturing unit near Aurangabad in Maharashtra.

What ails Indian pharmaceutical space? Here's what CCI says

Cardiac medicines accounted for the highest volumes in 2020. Despite the burden of diabetes rising, its share in volumes was low; however, its share in total value was higher

Johnson & Johnson plans to split into two companies

Johnson & Johnson is splitting into two companies, separating the division that sells Band-Aids and Listerine, from its medical device and prescription drug business. The company selling prescription drugs and medical devices will keep Johnson & Johnson as its name, the company said Friday. The new consumer health company will house brands including Neutrogena, Aveeno, Tylenol, Listerine, Johnson's, and Band-Aid. A name was not disclosed for the new company. Details are sparse, but the company expect the split to occur in the next two years. The announcement comes just days after General Electric said that it plans to split into three separate companies.

With Molnupiravir, India to get affordable weapon against Covid

With six Indian pharma companies working to manufacture antiviral pill Molnupiravir, healthcare experts say the game-changing drug will give India an effective and affordable weapon

Leading drug makers Sun Pharma, Lupin recall products in US market

According to USFDA, the Mumbai-based drug maker is recalling the affected lot due to "failed moisture limits."

Novartis cuts uneasy 20-year ties to Roche with $20.7-bn voting stake sale

The company is booking a capital gain of about $14 billion on the investment at a time when the cost of acquisitions in pharma have been soaring

Sun Pharma stock expected to keep market lead as firm recovers in US

Stock trading at the highest discount to ten-year valuation averages, as brokerages favour its US specialty portfolio.

DRL steps up Sputnik V supplies with second dose from Panacea Biotec

Hospital industry sources claim they want assurance on shelf life of imported vaccines

Drugs and Pharma sectors lead growth in India's exports from SEZs

Led by drugs and pharmaceuticals, India's exports from special economic Zones (SEZs) rose by 41.5 per cent on a year-on-year (YoY) basis to Rs 2.15 lakh crore in Q1FY22

Abbott introduces single-dose formulation of carbetocin in India

Drug major Abbott on Tuesday said it has launched room-temperature-stable, single-dose formulation of carbetocin in India to help in the prevention of postpartum haemorrhage (PPH)

Pharma industry to surpass $60 bn by FY24 from $45 bn in FY21: Report

The pandemic push will lead to an 11 per cent annual growth for the pharma sector over the next two years and help it surpass USD 60 billion from around USD 45 billion in FY21, according to a report.

3 reasons why pharma's 'underperformer' tag at markets could change soon

Resolution of supply chain issues, defensive buying and index inclusion are triggers

Work on non-Covid vaccines gives pharma firms an injection of hope

Approach drug regulator, seeking permission to conduct clinical trials

Mandaviya urges pharma industry to increase share of generic drugs in India

Union Health Minister Mansukh Mandaviya on Thursday urged the pharma industry to consider domestic manufacturing of medicines which are soon going to be off patent under Atmanirbhar Bharat

Back to old normal: Pharma industry returns to pre-pandemic growth level

In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector

South Korea's bio pharmaceutical exports ranks 7th in world amid Covid-19

Korea's bio pharmaceutical exports rose from 9th to 7th in the world last year

Small contract manufacturers wait to take a shot at Covid vaccines

A host of lesser-known vaccine makers are eyeing contract manufacturing opportunities for global and domestic majors

NPPA allows 50% price hike for ibuprofen, ranitidine, carbamazepine

These are scheduled drugs (or ones that are under price control) and low priced